source
- Drug makers and animal testing groups urge FDA to keep flexible guidance on animal studies for cancer drugsA coalition of drug developers, regulators and laboratory animal-testing organizations has asked the U.S. Food and Drug Administration to keep its guidance on cancer-drug safety studies flexible.…
- AbCellera reports striking Phase 2 results for hot-flash treatment, shares jump 31%AbCellera Biologics announced positive Phase 2 data for its neurokinin-3 receptor antagonist aimed at relieving vasomotor symptoms such as hot flashes. The company described the results as strikin…